What do we know about anticoagulation in patients with heart failure?

Current Opinion in Cardiology

Volumn 23, Issue 3, 2008, Pages 228-232

  Ahnert, Amy M ^a   Freudenberger, Ronald S ^a  

^a LEHIGH VALLEY HOSPITAL   (United States)

Author keywords

Anticoagulation; Heart failure; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; WARFARIN;

ANTICOAGULATION; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY THROMBOSIS; DISEASE SEVERITY; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

ANTICOAGULANTS; ASPIRIN; HEART FAILURE; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 41749088937     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3282fcd64d     Document Type: Review

References (28)

1. Meschia JF. Management of acute ischemic stroke. What is the role of tPA and antithrombotic agents? Postgrad Med 2000; 107:85-86. (89-93).
2. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160:3415-3420.
3. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151:933-938.
4. Isnard R, Komajda M. Thromboembolism in heart failure, old ideas and new challenges. Eur J Heart Fail 2001; 3:265-269.
5. Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA 1983; 250:2942-2946.
6. Freudenberger RS, Hellkamp AS, Mark DB, et al. Risk of thromboembolism in heart failure: an analysis from the sudden cardiac death in Heart Failure Trial (SCD-HeFT). Circulation 2007; 115:2637-2641. This recent analysis attempted to determine the incidence of and risk factors for thromboembolism in patients with systolic heart failure without a history of atrial fibrillation or atrial flutter. Hypertension at baseline and lower ejection fraction were independent predictors of risk.
7. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87 (6 Suppl):VI94-VI101.
8. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429-1435.
9. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997; 29:1074-1080.
10. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
11. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am J Cardiol 1987; 60:1340-1355.
12. Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000; 102:611-616.
13. Jafri SM, Ozawa T, Mammen E, et al. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993; 14:205-212.
14. Yamamoto K, Ikeda U, Furuhashi K, et al. The coagulation system is activated in idiopathic cardiomyopathy. J Am Coll Cardiol 1995; 25:1634-1640.
15. Sbarouni E, Bradshaw A, Andreotti F, et al. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am Heart J 1994; 127:607-612.
16. Chong AY, Freestone B, Patel J, et al. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes. Am J Cardiol 2006; 97:671-675.
17. Fischer D, Rossa S, Landmesser U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005; 26:65-69.
18. Loh E, Sutton MSJ, Wun C-CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997; 336:251-257.
19. Hays AG, Sacco RL, Rundek T, et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke 2006; 37:1715-1719.
20. Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. Neurology 2000; 54:288-294.
21. Katz SD, Marantz PR, Biasucci L, et al. Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J 1993; 126:141-146.
22. Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 148:157-164.
23. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004; 6:501-508.
24. Cokkinos DV, Haralabopoulos G, Kostis J, Toutouzas P. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006; 8:428-432.
25. Hart RG, Halperin JL, Pearce LA, et al. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med 2003; 138:831-838.
26. Parkash R, Wee V, Gardner MJ, et al. The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. Can J Cardiol 2007; 23:457-461.
27. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115:2689-2696. This was an observational study, which attempted to define bleeding risks of elderly patients, newly initiated on coumadin for atrial fibrillation.
28. Pullicino P, Thompson JL, Barton B, et al. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail 2006; 12:39-46.